Clinical Trial Update: An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury [Phase 2]

View source ↗

Summary

The document provides an update on a Phase 2 trial evaluating JNJ-17299425 in participants with traumatic brain injury, noting that the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• JNJ-17299425

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Traumatic Brain Injury | Phase 2 | Status: TERMINATED